Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration
- PMID: 16905558
- DOI: 10.1093/hmg/ddl220
Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration
Abstract
Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world and complement factor H (CFH) polymorphism has been found to associated with the AMD. We performed a meta-analysis to estimate the magnitude of the gene effect and the possible mode of action. A meta-analysis of eight studies assessing association between the CFH Y402H polymorphism and AMD was performed. Data extraction and study quality assessment were performed in duplicate, and heterogeneity and publication bias were explored. There was strong evidence for association between CFH and AMD, with those having CC and TC genotypes being roughly six and 2.5 times more likely to have AMD than patients with TT genotype, suggesting a co-dominant, multiplicative genetic model. The population attributable risk for the CC/TC genotype is 58.9%, i.e. the CFH polymorphism is involved in over half of all AMD. This meta-analysis summarizes the strong evidence for an association between CFH and AMD and indicates a multiplicative model with each C allele increasing the odds of AMD by approximately 2.5-fold. This result is at least as important at the population level as ApoE4 and Alzheimer's disease, playing a role in almost 60% of AMD at the population level.
Similar articles
-
Association of risk genotypes of ARMS2/LOC387715 A69S and CFH Y402H with age-related macular degeneration with and without reticular pseudodrusen: a meta-analysis.Acta Ophthalmol. 2018 Mar;96(2):e105-e110. doi: 10.1111/aos.13494. Epub 2017 Jun 8. Acta Ophthalmol. 2018. PMID: 28593728 Review.
-
Age-related macular degeneration and association of CFH Y402H and LOC387715 A69S polymorphisms in a Turkish population.DNA Cell Biol. 2012 Mar;31(3):323-30. doi: 10.1089/dna.2011.1214. Epub 2011 Jul 26. DNA Cell Biol. 2012. PMID: 21790300
-
Joint association of complement component 3 and CC-cytokine ligand2 (CCL2) or complement component 3 and CFH polymorphisms in age-related macular degeneration.Ophthalmic Genet. 2017 Jul-Aug;38(4):365-370. doi: 10.1080/13816810.2016.1242019. Epub 2017 Jan 17. Ophthalmic Genet. 2017. PMID: 28095095
-
Evaluation of CC-cytokine ligand 2 and complementary factor H Y402H polymorphisms and their interactional association with age-related macular degeneration.Acta Ophthalmol. 2016 Dec;94(8):e779-e785. doi: 10.1111/aos.13143. Epub 2016 Jun 18. Acta Ophthalmol. 2016. PMID: 27316788
-
Association of ARMS2/LOC387715 A69S, CFH Y402H, and CFH I62V polymorphisms with retinal angiomatous proliferation compared with typical age-related macular degeneration: a meta-analysis.Int Ophthalmol. 2017 Dec;37(6):1397-1409. doi: 10.1007/s10792-016-0413-2. Epub 2016 Dec 22. Int Ophthalmol. 2017. PMID: 28005184 Review.
Cited by
-
Immunogenetic and Environmental Factors in Age-Related Macular Disease.Int J Mol Sci. 2024 Jun 14;25(12):6567. doi: 10.3390/ijms25126567. Int J Mol Sci. 2024. PMID: 38928273 Free PMC article. Review.
-
PolySialic Acid Nanoparticles Actuate Complement-Factor-H-Mediated Inhibition of the Alternative Complement Pathway: A Safer Potential Therapy for Age-Related Macular Degeneration.Pharmaceuticals (Basel). 2024 Apr 17;17(4):517. doi: 10.3390/ph17040517. Pharmaceuticals (Basel). 2024. PMID: 38675477 Free PMC article.
-
Exogenous CFH Modulates Levels of Pro-Inflammatory Mediators to Prevent Oxidative Damage of Retinal Pigment Epithelial Cells with the At-Risk CFH Y402H Variant.Antioxidants (Basel). 2023 Jul 31;12(8):1540. doi: 10.3390/antiox12081540. Antioxidants (Basel). 2023. PMID: 37627535 Free PMC article.
-
Physiology and pathology of the C3 amplification cycle: A retrospective.Immunol Rev. 2023 Jan;313(1):217-224. doi: 10.1111/imr.13165. Epub 2022 Nov 21. Immunol Rev. 2023. PMID: 36408746 Free PMC article. Review.
-
A Phase I, Single Ascending Dose Study of GEM103 (Recombinant Human Complement Factor H) in Patients with Geographic Atrophy.Ophthalmol Sci. 2022 Apr 11;2(2):100154. doi: 10.1016/j.xops.2022.100154. eCollection 2022 Jun. Ophthalmol Sci. 2022. PMID: 36249705 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous